| Project/Area Number |
25462603
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
Haruta Shoji 奈良県立医科大学, 医学部, 助教 (30448766)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOBAYASHI Hiroshi 奈良県立医科大学, 医学部, 教授 (40178330)
OI Hidekazu 近畿大学, 医学部附属病院, 教授 (10283368)
KAWAGUCHI Ryuji 奈良県立医科大学, 医学部, 講師 (50382289)
ITO Fuminori 奈良県立医科大学, 医学部, 助教 (20553241)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 大豆ビクニン / がん転移抑制薬 / 分子標的薬 / 低分子薬 / 卵巣癌 |
|---|
| Outline of Final Research Achievements |
We already developed a cancer metastasis inhibitor named bikunin which has no side effects. In a clinical study which intravenously administered the inhibitor for patients with advanced ovarian cancer, improvement was found in 5-year survival rate. The present study revealed that oral administration of soybean bikunin, which is contained in the waste produced by purifying soy protein, suppressed cancer metastasis in tumor-bearing mice. We also performed molecular simulation to develop low molecular compounds simulating the action of soybean bikunin. Subsequently, we selected a low molecular weight substance of bikunin which had the highest affinity to bikunin receptors, and designed and made samples of a lead compound. We believe that if we can develop low molecular compounds of bikunin which can be administered orally by the present study, it would contribute to not only to improve prognosis of patients with ovarian cancer, but also to improve QOL of patients.
|
